Copy Link Print Information

Elacridar

(Synonyms: GF120918; GW0918; GG918; GW120918)
31 Cited Publications
고객리뷰

Based on 31 publication(s) in Google Scholar

Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • Purity: 99.66%
  • CAS No.: 143664-11-3
  • 화학식: C34H33N3O5
  • 분자량:563.64
  • 보관:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Elacridar Chemical Structure
    Elacridar Chemical Structure
  • Experimental Validation Results for Elacridar
  • Experimental Validation Results for Elacridar
  • Experimental Validation Results for Elacridar
  • Experimental Validation Results for Elacridar
  • Experimental Validation Results for Elacridar
  • Experimental Validation Results for Elacridar
  • Experimental Validation Results for Elacridar
  • Experimental Validation Results for Elacridar
  • Experimental Validation Results for Elacridar
CAS No.: 143664-11-3
사이즈
가격
재고
수량
Amount: USD 0.00
Please select quantity
or
or

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Elacridar:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
주변의 대리점 찾기 Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • 용액&용해도
  • 순도&문서
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Elacridar

More
Customer Validation & Images
IFIn Vivo Efficacy StudyHistological Imaging/StainingCell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • IF
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Histological Imaging/Staining
  • IF
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
Keywords
MOQ
Minimum order quantity
100 mg

견적 받기 해외재고보유

Other size
견적 받기
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress 로그인
Register
Sign in to MedChemExpress
회원가입

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Elacridar Chemical Structure
    Elacridar Chemical Structure
    1/16
  • 1/16

    Elacridar purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2024 Nov 25:217355. [Abstract]

    Customer Validation
     ABCB1 inhibition significantly reduced the number of 22Rv1-DR PCa cell-derived colonies compared to docetaxel treatment alone. Treatment with 2 μM Elacridar as a single agent did not impact colony growth in DR cells.

  • 1/16

    Elacridar purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Oct 20;9(42):eabp9530. [Abstract]

    Customer Validation
     Elacridar (200 nM) increased the sensitivity of BCBM organoids to doxorubicin by immunofluorescent staining.

  • 1/16

    Elacridar purchased from MedChemExpress. Usage Cited in: Mol Psychiatry. 2023 Sep;28(9):3930-3942. [Abstract]

    Customer Validation
     Systemic ivabradine administration (0,3,10 mg/kg; i.p.) following Elacridar hydrochloride (5 mg/kg; i.v.; single dose), dose-dependently decreased the mean number of active lever presses and cocaine infusions under an FR2 reinforcement schedule.

  • 1/16

    Elacridar purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2021 Sep:193:105124. [Abstract]

    Customer Validation
     Elacridar (0-33.34 μM, 72 h) do not induce cell toxicity by MTT assay.

  • 1/16

    Elacridar purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2019 Mar 5;20(5). pii: E1125. [Abstract]

    Customer Validation
     Sensitization of resistant cells to chemotherapy by Elacridar (5 μM) treatment.

  • 1/16

    Elacridar purchased from MedChemExpress. Usage Cited in: J Mater Chem B. 2018 Dec 7;6(45):7521-7529. [Abstract]

    Customer Validation
     Elacridar hydrochloride (0.25 mg/kg; i.v.; every two days for a total of five doses). Ex vivo histological analyses of tumor sections excised from mice bearing MCF-7/ADR tumors after treatment. Nuclei were stained blue, and the extracellular matrix and cytoplasm were stained red through respectively. H&E staining images of the heart of MCF-7/ADR tumor-bearing mice after treatment. Scale bars represent 50 μM.

  • 1/16

    Elacridar purchased from MedChemExpress. Usage Cited in: J Mater Chem B. 2018 Dec 7;6(45):7521-7529. [Abstract]

    Customer Validation
     Bioactivity inhibition of the P-gp protein in MCF-7/ADR cells using the immunofluorescence assay after incubation with different samples. Green fluorescence: P-gp proteins labelled with FITC-antibody; blue fluorescence: nuclei stained with DAPI. The scale bars represent 20 mm. DOX concentration if applied: 10 mg/mL; Elacridar hydrochloride concentration if applied: 0.5 mg/mL.

  • 1/16

    Elacridar purchased from MedChemExpress. Usage Cited in: J Mater Chem B. 2018 Dec 7;6(45):7521-7529. [Abstract]

    Customer Validation
     Elacridar hydrochloride (0.25 mg/kg; i.v.; every two days for a total of five doses) co-delivered with DOX, exhibited a synergistic anticancer effect on multidrug-resistant MCF-7/ADR tumors in xenograft mouse models.

  • 1/16

    Elacridar purchased from MedChemExpress. Usage Cited in: J Drug Target. 2016;24(5):441-9. [Abstract]

    Customer Validation
     Cells are co-treated with 5 μM of free LY139481 or an equivalent dose of SMA-LY139481 and either vehicle control (0.01% DMSO), Elacridar (1 μM), KO143 (5 μM), Valspodar (1 μM) or a combination of efflux inhibitors for 6 h.

  • Elacridar